Nanotechnology in Cosmetics
Nanotechnology is a growing business worldwide. Nanomaterials are increasingly used in cosmetics and personal care products. Nanomaterials are similar to other chemicals/substances, but there are risks associated to specific nanomaterials and their use. In the EU, cosmetic products containing nanomaterials may have to be notified by the Responsible Person six months before being placed on the market.

NANOMATERIALS EU LEGAL FRAMEWORK

According to the European Regulation (EC) No 1223/2009 on cosmetic products, nanomaterial means “an insoluble or bio-persistent and intentionally manufactured material whit one or more external dimensions, or an internal structure, on the scale from 1 to 100 nm”. This definition may suffer adjustments in the future by the Commission, in line with the constant technical and scientific developments seen in the field of nanotechnologies.

All cosmetic products that contain nanomaterials shall be subject to a higher level of protection of human health. This means that, when notifying a cosmetic product, the presence substances in the nano form needs to be duly identified.

Cosmetic products containing nanomaterials must be notified by the Responsible Person (by electronic means) six months before being placed on the market. They must be authorized by the European Commission prior to their use in cosmetic and personal care products. This does not apply when the nanomaterials are used as colourants, UV-filters or preservatives and are already included in the Annexes of the European Regulation (the “positive” lists).

The notification of cosmetic products containing nanomaterials has to include, at least:
• Identification of the nanomaterial (including its chemical name – IUPAC);
• Specification of the nanomaterial (size of particles, physical and chemical properties);
• Estimation of the quantity of nanomaterial contained in cosmetic products intended to be placed on the market per year;
• Toxicological profile of the nanomaterial;
• Safety data of the nanomaterial relating to the category of cosmetic product (as used in such products);
• Reasonably foreseeable exposure conditions.

If there are any concerns regarding the safety of a nanomaterial, the European Commission shall request the Scientific Committee on Consumer Safety (SCCS) to give its opinion on the safety of such nanomaterial for use in the relevant categories of cosmetic products and on the reasonably foreseeable exposure conditions. If, according to the SCCS final opinion, there is a potential risk to human health, including when there is insufficient data, the Commission shall put in place the necessary risk management measures and may amend Annexes II and III (list of prohibited substances in cosmetics and list of substances which cosmetic products must not contain except subject to the restrictions laid down).

SAFETY OF NANOMATERIALS IN COSMETICS

Until now, the concerns of the Commission that gave origin to requests of the SCCS opinions have been base on the intrinsic properties of nanomaterials, as a category, because of their nano-scale dimension, bio-persistence and insolubility.

The SCCS reviews submitted toxicological data and publishes its opinion on the safety of the ingredients in cosmetics. Several opinions on ingredients in the nano form have been published by the SCCS (like, colloidal silver, styrene/acrylates polymer, copper and colloidal copper, hydroxyapatite, silica, and others).

March this year, the European Commission’s SCCS has published a scientific advice on the safety of nanomaterials in cosmetics (SCCS/1618/20). The SCCS has identified certain aspects of nanomaterials that constitute a basis for concern over safety to consumers’ health when used in cosmetic products. Physicochemical aspects (like the very small dimensions, solubility/persistence, etc.), exposure aspects (such as frequency and amounts used, etc.) and other aspects (like novel properties, activity or function, etc.) were among the attributes considered.

Previous inconclusive opinions on three different nanomaterials were reviewed. With further relevant information available in published literature, the SCCS identified certain features related to each of the nanomaterials that raise a safety concern (described in the annexes of the scientific advice).

In sum, nanotechnology used in cosmetics may represent a step forward in innovation but it may also represent a risk to consumers health. Cosmetic companies that intend to use nanomaterials (not yet present in the Annexes of the Europeans Cosmetic Regulation) in their products must prepare a dossier with all documentation regarding these compounds. This process might be complicated and lead to increased costs for cosmetic companies

We can help you to successfully follow through this process. For more information, feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Scientific Committee on Consumer Safety (SCCS). Scientific Advice on the safety of nanomaterials in cosmetics (SCCS/1618/20). Available at: https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_239.pdf

further
reading

news & updates

EU Ecolabel adoption and recognition are on the rise

The Ecolabel certification is a comprehensive program focused on fostering sustainable practices. It evaluates products based on life cycle assessments, where every phase of said life cycle must abide by strict standards to attain the Ecolabel certification. The overarching objective of this certification is minimizing environmental harm from production or consumption activities.

Read More »
news & updates

SCCS preliminary opinion on Citral sensitization endpoint

Ingredients: CITRAL

Date of publication: 27/03/2024

On March 27 2024, the Scientific Committee on Consumer Safety (SCCS) published the Preliminary Opinion on the safety of Citral in cosmetic products. The deadline for comments is set to June 2, 2024.

Read More »
cosmetic products

UK proposes ban of wet wipes containing plastic 

The UK has proposed, on April 24, 2024, a regulation titled The Environmental Protection (Wet Wipes Containing Plastic) (England) Regulations 2024, to the World Trade Organization (WTO). The regulation aims to eliminate the supply and sale of plastic-containing wet wipes, including cosmetic ones. The public can offer comments on the draft until June 23, 2024, with adoption expected in September of the same year.

Read More »
medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »